Subsite-specific benefit of induction chemoimmunotherapy in HPV-negative oropharyngeal squamous cell carcinoma - Takeaways - MDSpire

Subsite-specific benefit of induction chemoimmunotherapy in HPV-negative oropharyngeal squamous cell carcinoma

  • By

  • Lin Zhu

  • Die Zhang

  • Jie Chen

  • Wei Qian

  • Peiyao Liu

  • Chunying Shen

  • Tingting Xu

  • Xin Zhou

  • Xueguan Lu

  • June 11, 2026

  • 0 min

Share

  • 1

    The study evaluated the addition of immune checkpoint inhibitors to induction chemotherapy in HPV-negative oropharyngeal squamous cell carcinoma.

  • 2

    A total of 99 patients were analyzed, with 73 receiving induction chemotherapy alone and 26 receiving chemotherapy plus immune checkpoint inhibitors.

  • 3

    In the non-base-of-tongue cohort, the addition of immune checkpoint inhibitors significantly improved progression-free survival.

  • 4

    Overall, the addition of immune checkpoint inhibitors showed numerically improved progression-free and overall survival, but differences were not statistically significant.

  • 5

    The study suggests a potential benefit of immunotherapy in non-base-of-tongue tumors, warranting further prospective validation.

Original Source(s)

Subsite-specific benefit of induction chemoimmunotherapy in HPV-negative oropharyngeal squamous cell carcinoma

  • by Lin Zhu, Die Zhang, Jie Chen, Wei Qian, Peiyao Liu, Chunying Shen, Tingting Xu, Xin Zhou, Xueguan Lu

  • June 11, 2026

Related Content

Origins of CD8 tissue resident memory

Editorial: Integrating nutrition in cancer therapy: approaches to improve patient outcomes and survival

Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma